Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review

por Rhyne, Christopher, Cohen, Joshua M., Seminerio, Michael J., Carr, Karen, Krasenbaum, Lynda J.
Publicado 2023

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

por Silberstein, Stephen D., Cohen, Joshua M., Seminerio, Michael J., Yang, Ronghua, Ashina, Sait, Katsarava, Zaza
Publicado 2020

Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments

por Nissan, George R., Kim, Richard, Cohen, Joshua M., Seminerio, Michael J., Krasenbaum, Lynda J., Carr, Karen, Martin, Vincent
Publicado 2022

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study

por Blumenfeld, Andrew M., Stevanovic, Darko M., Ortega, Mario, Cohen, Joshua M., Seminerio, Michael J., Yang, Ronghua, Jiang, Bo, Tepper, Stewart J.
Publicado 2020

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

por Lipton, Richard B., Cohen, Joshua M., Bibeau, Kristen, Galic, Maja, Seminerio, Michael J., Ramirez Campos, Verena, Halker Singh, Rashmi B., Ailani, Jessica
Publicado 2020

Immunogenicity of biologic therapies for migraine: a review of current evidence

por Cohen, Joshua M., Ning, Xiaoping, Kessler, Yoel, Rasamoelisolo, Michele, Campos, Verena Ramirez, Seminerio, Michael J., Krasenbaum, Lynda J., Shen, Honglue, Stratton, Jennifer
Publicado 2021

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

por Silberstein, Stephen D., Reshef, Shoshana, Cohen, Joshua M., Gandhi, Sanjay, Seminerio, Michael, Ramirez Campos, Verena, Kessler, Yoel, Thompson, Stephen F., Blumenfeld, Andrew
Publicado 2022

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

por Lipton, Richard B., Cohen, Joshua M., Galic, Maja, Seminerio, Michael J., Yeung, Paul P., Aycardi, Ernesto, Bigal, Marcelo E., Bibeau, Kristen, Buse, Dawn C.
Publicado 2021

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study

por Driessen, Maurice T., Cohen, Joshua M., Patterson-Lomba, Oscar, Thompson, Stephen F., Seminerio, Michael, Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Publicado 2022

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

por Driessen, Maurice T., Cohen, Joshua M., Thompson, Stephen F., Patterson-Lomba, Oscar, Seminerio, Michael J., Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Publicado 2022